Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465835) titled 'A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)' on March 4.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Electra Therapeutics Inc.
Condition:
T Cell Malignancies
Intervention:
Drug: ELA026
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: February 17, 2026
Target Sample Size: 84
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07465835
Published b...